Selected research
Industry Research
Genetic COPD Industry Research Report 2026
Market perspective
The global Genetic COPD market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Genetic COPD market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Genetic COPD market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Genetic COPD market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Genetic COPD include Takeda, Pfizer, GlaxoSmithKline, Baxter, AstraZeneca, Vertex Pharmaceuticals, Teva Pharmaceutical Industries, ProMetic Life Sciences and ProBioGen, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Genetic COPD market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Genetic COPD.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Genetic COPD Market by Company
Takeda
Pfizer
GlaxoSmithKline
Baxter
AstraZeneca
Vertex Pharmaceuticals
Teva Pharmaceutical Industries
ProMetic Life Sciences
ProBioGen
LFB Biomedicaments
Kedrion Group
Kamada Ltd
Grifols
CSL Behring
Chiesi Pharmaceuticals
Boehringer Ingelheim
Biogen
Baxalta
Arrowhead Research Corporation
Abeona Therapeutics
Genetic COPD Segment by Type
Augmentation Therapy
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Other
Genetic COPD Segment by Application
Specialty Clinics
Hospitals
Pharmacies
Others
Genetic COPD Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Genetic COPD market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Genetic COPD and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Genetic COPD.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Genetic COPD companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Augmentation Therapy
- Cystic Fibrosis(CF)
- Non-CF Bronchiectasis(NCFB)
- Other
Applications
- Specialty Clinics
- Hospitals
- Pharmacies
- Others
Companies covered
- Takeda
- Pfizer
- GlaxoSmithKline
- Baxter
- AstraZeneca
- Vertex Pharmaceuticals
- Teva Pharmaceutical Industries
- ProMetic Life Sciences
- ProBioGen
- LFB Biomedicaments
- Kedrion Group
- Kamada Ltd
- Grifols
- CSL Behring
- Chiesi Pharmaceuticals
- Boehringer Ingelheim
- Biogen
- Baxalta
- Arrowhead Research Corporation
- Abeona Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Genetic COPD by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Augmentation Therapy
- 2.2.3 Cystic Fibrosis(CF)
- 2.2.4 Non-CF Bronchiectasis(NCFB)
- 2.2.5 Other
- 2.3 Genetic COPD by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Specialty Clinics
- 2.3.3 Hospitals
- 2.3.4 Pharmacies
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Genetic COPD Breakdown Data by Type
- 3.1 Global Genetic COPD Historic Market Size by Type (2021-2026)
- 3.2 Global Genetic COPD Forecasted Market Size by Type (2027-2032)
4 Genetic COPD Breakdown Data by Application
- 4.1 Global Genetic COPD Historic Market Size by Application (2021-2026)
- 4.2 Global Genetic COPD Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Genetic COPD Market Perspective (2021-2032)
- 5.2 Global Genetic COPD Growth Trends by Region
- 5.2.1 Global Genetic COPD Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Genetic COPD Historic Market Size by Region (2021-2026)
- 5.2.3 Genetic COPD Forecasted Market Size by Region (2027-2032)
- 5.3 Genetic COPD Market Dynamics
- 5.3.1 Genetic COPD Industry Trends
- 5.3.2 Genetic COPD Market Drivers
- 5.3.3 Genetic COPD Market Challenges
- 5.3.4 Genetic COPD Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Genetic COPD Players by Revenue
- 6.1.1 Global Top Genetic COPD Players by Revenue (2021-2026)
- 6.1.2 Global Genetic COPD Revenue Market Share by Players (2021-2026)
- 6.2 Global Genetic COPD Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Genetic COPD Head Office and Area Served
- 6.4 Global Genetic COPD Players, Product Type & Application
- 6.5 Global Genetic COPD Manufacturers Established Date
- 6.6 Global Genetic COPD Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Genetic COPD Market Size (2021-2032)
- 7.2 North America Genetic COPD Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Genetic COPD Market Size by Country (2021-2026)
- 7.4 North America Genetic COPD Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Genetic COPD Market Size (2021-2032)
- 8.2 Europe Genetic COPD Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Genetic COPD Market Size by Country (2021-2026)
- 8.4 Europe Genetic COPD Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Genetic COPD Market Size (2021-2032)
- 9.2 Asia-Pacific Genetic COPD Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Genetic COPD Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Genetic COPD Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Genetic COPD Market Size (2021-2032)
- 10.2 South America Genetic COPD Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Genetic COPD Market Size by Country (2021-2026)
- 10.4 South America Genetic COPD Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Genetic COPD Market Size (2021-2032)
- 11.2 Middle East & Africa Genetic COPD Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Genetic COPD Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Genetic COPD Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda
- 12.1.1 Takeda Company Information
- 12.1.2 Takeda Business Overview
- 12.1.3 Takeda Revenue in Genetic COPD Business (2021-2026)
- 12.1.4 Takeda Genetic COPD Product Portfolio
- 12.1.5 Takeda Recent Developments
- 12.2 Pfizer
- 12.2.1 Pfizer Company Information
- 12.2.2 Pfizer Business Overview
- 12.2.3 Pfizer Revenue in Genetic COPD Business (2021-2026)
- 12.2.4 Pfizer Genetic COPD Product Portfolio
- 12.2.5 Pfizer Recent Developments
- 12.3 GlaxoSmithKline
- 12.3.1 GlaxoSmithKline Company Information
- 12.3.2 GlaxoSmithKline Business Overview
- 12.3.3 GlaxoSmithKline Revenue in Genetic COPD Business (2021-2026)
- 12.3.4 GlaxoSmithKline Genetic COPD Product Portfolio
- 12.3.5 GlaxoSmithKline Recent Developments
- 12.4 Baxter
- 12.4.1 Baxter Company Information
- 12.4.2 Baxter Business Overview
- 12.4.3 Baxter Revenue in Genetic COPD Business (2021-2026)
- 12.4.4 Baxter Genetic COPD Product Portfolio
- 12.4.5 Baxter Recent Developments
- 12.5 AstraZeneca
- 12.5.1 AstraZeneca Company Information
- 12.5.2 AstraZeneca Business Overview
- 12.5.3 AstraZeneca Revenue in Genetic COPD Business (2021-2026)
- 12.5.4 AstraZeneca Genetic COPD Product Portfolio
- 12.5.5 AstraZeneca Recent Developments
- 12.6 Vertex Pharmaceuticals
- 12.6.1 Vertex Pharmaceuticals Company Information
- 12.6.2 Vertex Pharmaceuticals Business Overview
- 12.6.3 Vertex Pharmaceuticals Revenue in Genetic COPD Business (2021-2026)
- 12.6.4 Vertex Pharmaceuticals Genetic COPD Product Portfolio
- 12.6.5 Vertex Pharmaceuticals Recent Developments
- 12.7 Teva Pharmaceutical Industries
- 12.7.1 Teva Pharmaceutical Industries Company Information
- 12.7.2 Teva Pharmaceutical Industries Business Overview
- 12.7.3 Teva Pharmaceutical Industries Revenue in Genetic COPD Business (2021-2026)
- 12.7.4 Teva Pharmaceutical Industries Genetic COPD Product Portfolio
- 12.7.5 Teva Pharmaceutical Industries Recent Developments
- 12.8 ProMetic Life Sciences
- 12.8.1 ProMetic Life Sciences Company Information
- 12.8.2 ProMetic Life Sciences Business Overview
- 12.8.3 ProMetic Life Sciences Revenue in Genetic COPD Business (2021-2026)
- 12.8.4 ProMetic Life Sciences Genetic COPD Product Portfolio
- 12.8.5 ProMetic Life Sciences Recent Developments
- 12.9 ProBioGen
- 12.9.1 ProBioGen Company Information
- 12.9.2 ProBioGen Business Overview
- 12.9.3 ProBioGen Revenue in Genetic COPD Business (2021-2026)
- 12.9.4 ProBioGen Genetic COPD Product Portfolio
- 12.9.5 ProBioGen Recent Developments
- 12.10 LFB Biomedicaments
- 12.10.1 LFB Biomedicaments Company Information
- 12.10.2 LFB Biomedicaments Business Overview
- 12.10.3 LFB Biomedicaments Revenue in Genetic COPD Business (2021-2026)
- 12.10.4 LFB Biomedicaments Genetic COPD Product Portfolio
- 12.10.5 LFB Biomedicaments Recent Developments
- 12.11 Kedrion Group
- 12.11.1 Kedrion Group Company Information
- 12.11.2 Kedrion Group Business Overview
- 12.11.3 Kedrion Group Revenue in Genetic COPD Business (2021-2026)
- 12.11.4 Kedrion Group Genetic COPD Product Portfolio
- 12.11.5 Kedrion Group Recent Developments
- 12.12 Kamada Ltd
- 12.12.1 Kamada Ltd Company Information
- 12.12.2 Kamada Ltd Business Overview
- 12.12.3 Kamada Ltd Revenue in Genetic COPD Business (2021-2026)
- 12.12.4 Kamada Ltd Genetic COPD Product Portfolio
- 12.12.5 Kamada Ltd Recent Developments
- 12.13 Grifols
- 12.13.1 Grifols Company Information
- 12.13.2 Grifols Business Overview
- 12.13.3 Grifols Revenue in Genetic COPD Business (2021-2026)
- 12.13.4 Grifols Genetic COPD Product Portfolio
- 12.13.5 Grifols Recent Developments
- 12.14 CSL Behring
- 12.14.1 CSL Behring Company Information
- 12.14.2 CSL Behring Business Overview
- 12.14.3 CSL Behring Revenue in Genetic COPD Business (2021-2026)
- 12.14.4 CSL Behring Genetic COPD Product Portfolio
- 12.14.5 CSL Behring Recent Developments
- 12.15 Chiesi Pharmaceuticals
- 12.15.1 Chiesi Pharmaceuticals Company Information
- 12.15.2 Chiesi Pharmaceuticals Business Overview
- 12.15.3 Chiesi Pharmaceuticals Revenue in Genetic COPD Business (2021-2026)
- 12.15.4 Chiesi Pharmaceuticals Genetic COPD Product Portfolio
- 12.15.5 Chiesi Pharmaceuticals Recent Developments
- 12.16 Boehringer Ingelheim
- 12.16.1 Boehringer Ingelheim Company Information
- 12.16.2 Boehringer Ingelheim Business Overview
- 12.16.3 Boehringer Ingelheim Revenue in Genetic COPD Business (2021-2026)
- 12.16.4 Boehringer Ingelheim Genetic COPD Product Portfolio
- 12.16.5 Boehringer Ingelheim Recent Developments
- 12.17 Biogen
- 12.17.1 Biogen Company Information
- 12.17.2 Biogen Business Overview
- 12.17.3 Biogen Revenue in Genetic COPD Business (2021-2026)
- 12.17.4 Biogen Genetic COPD Product Portfolio
- 12.17.5 Biogen Recent Developments
- 12.18 Baxalta
- 12.18.1 Baxalta Company Information
- 12.18.2 Baxalta Business Overview
- 12.18.3 Baxalta Revenue in Genetic COPD Business (2021-2026)
- 12.18.4 Baxalta Genetic COPD Product Portfolio
- 12.18.5 Baxalta Recent Developments
- 12.19 Arrowhead Research Corporation
- 12.19.1 Arrowhead Research Corporation Company Information
- 12.19.2 Arrowhead Research Corporation Business Overview
- 12.19.3 Arrowhead Research Corporation Revenue in Genetic COPD Business (2021-2026)
- 12.19.4 Arrowhead Research Corporation Genetic COPD Product Portfolio
- 12.19.5 Arrowhead Research Corporation Recent Developments
- 12.20 Abeona Therapeutics
- 12.20.1 Abeona Therapeutics Company Information
- 12.20.2 Abeona Therapeutics Business Overview
- 12.20.3 Abeona Therapeutics Revenue in Genetic COPD Business (2021-2026)
- 12.20.4 Abeona Therapeutics Genetic COPD Product Portfolio
- 12.20.5 Abeona Therapeutics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst